KlothovsTesamorelin + Ipamorelin

Klotho is a single-pass transmembrane protein primarily expressed in the kidney, parathyroid gland, and choroid plexus, with a soluble form (s-Klotho) cleaved from the membrane and circulating systemically as an endocrine factor. It exists in three forms — alpha-Klotho (the most studied, anti-ageing form), beta-Klotho (which partners with FGF21), and gamma-Klotho — each with distinct receptor partnerships and tissue effects.

At the receptor level, alpha-Klotho is the obligate co-receptor for fibroblast growth factor 23 (FGF23), enabling FGF23 to bind and activate FGFR1 receptors in the kidney to regulate phosphate excretion. This makes Klotho a central node in mineral metabolism. Beyond this canonical role, soluble Klotho exerts numerous endocrine effects: it inhibits the IGF-1/insulin signalling pathway (a conserved longevity mechanism shared with caloric restriction), enhances expression of antioxidant enzymes via FoxO transcription factor activation, suppresses Wnt signalling (reducing stem cell exhaustion), inhibits TGF-beta signalling (preventing fibrosis), and blocks NF-kB and NLRP3 inflammasome activation (reducing inflammaging).

The ageing phenotype connection is striking: mice lacking Klotho develop multi-organ ageing — atherosclerosis, osteoporosis, skin atrophy, cognitive decline — within weeks of birth, while mice with elevated Klotho expression live up to 30% longer than controls. In humans, circulating Klotho levels decline with age, and lower levels associate with increased mortality and chronic disease risk in observational studies. Recombinant alpha-Klotho is in early clinical development as a potential therapy for chronic kidney disease, cognitive decline, and broader age-related diseases. The 2026 research wave around Klotho has positioned it as one of the most promising single-protein interventions in the longevity field, though no therapeutic Klotho product is yet approved for human use.

The Tesamorelin + Ipamorelin combination pairs the only FDA-approved GHRH analogue with the most selective growth hormone secretagogue, creating a dual-pathway approach similar in principle to CJC-1295/Ipamorelin but with tesamorelin's unique advantages for body composition.

Tesamorelin activates the GHRH receptor on pituitary somatotrophs through the Gs/cAMP/PKA pathway, stimulating GH gene transcription and secretion. Its trans-3-hexenoic acid modification at position 1 provides enhanced receptor affinity and modest DPP-IV resistance compared to native GHRH. Ipamorelin simultaneously activates the GHS-R1a receptor via the Gq/11/PLC/calcium pathway, providing the same synergistic amplification of GH pulses described for the CJC/Ipa combination.

The distinguishing advantage of tesamorelin in this stack is its clinically demonstrated effect on visceral adipose tissue (VAT). In multiple randomized controlled trials for HIV-associated lipodystrophy, tesamorelin reduced trunk fat by 15-18% over 6 months, with visceral fat reduction being proportionally greater than subcutaneous fat reduction. This preferential visceral fat mobilization occurs because visceral adipocytes express the highest density of GH receptors and are most responsive to GH-mediated hormone-sensitive lipase activation. The GH elevations produced by tesamorelin/ipamorelin combination may be greater than tesamorelin alone (due to the synergistic dual-pathway effect), potentially enhancing this visceral fat-targeting effect. The combination also benefits from tesamorelin's full-length GHRH sequence (44 amino acids vs 29 for CJC-1295), which may provide more complete receptor activation, and from the preserved pulsatility that both agents maintain through intact somatostatin feedback regulation.